Inhibrx, a biologic therapeutic company focused on the treatment of high unmet medical needs in oncology, infectious disease and inflammatory conditions, and The Alpha-1 Project, Inc. (TAP), a wholly owned subsidiary of the Alpha-1 ... Read more